Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 14/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 2/20 | 0.36 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SI | P14410 | 2/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044146 | 0.85 | HCAR3 (0.42) | HCAR3HPGDHCAR2 | |
| SCHEMBL6044413 | 0.76 | HCAR3 (0.44) | HCAR3TTRHPGDHCAR2 | |
| SCHEMBL6043680 | 0.75 | HCAR3 (0.68) | HCAR3HPGDHCAR2 | |
| SCHEMBL6044212 | 0.74 | KDM4C (0.34) | HCAR3 | |
| SCHEMBL6044270 | 0.73 | KDM4C (0.40) | HCAR3MGAMAMY1AGAASI | |
| SCHEMBL6044262 | 0.69 | HCAR3 (0.58) | HCAR3TTRMGAMAMY1AGAA | |
| SCHEMBL6044800 | 0.68 | HCAR3 (0.60) | HCAR3TTRGAA | |
| SCHEMBL6044659 | 0.66 | HCAR3 (0.39) | HCAR3MGAMAMY1AGAASI | |
| SCHEMBL6043601 | 0.65 | KDM4C (0.34) | — | |
| SCHEMBL16759801 | 0.64 | ALDH1A1 (0.40) | TTRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2004041274-A1 | BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | GCGR, GPR119, HMGCR | HCAR3 85/4885TTR 3065/4885MGAM 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.